SCHEMBL2745822

SCHEMBL2745822

CN(C)C(=O)C(C)(C)N

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6448524 0.97 ALDH1A1 (0.33)
Trifluoroacetic Acid SCHEMBL2493343 0.85 NOS1 (0.34)
SCHEMBL13072431 0.81
SCHEMBL1860593 0.79
SCHEMBL8262641 0.77
SCHEMBL19669088 0.77
SCHEMBL1106444 0.76
SCHEMBL16944043 0.73 ALDH1A1 (0.39)
SCHEMBL12916754 0.73 DPP4 (0.31)
SCHEMBL63072 0.73 MLYCD (0.31)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260027090-A1 Methods of Inhibiting Osteoclastogenesis and Osteoclast Activity VTV THERAPEUTICS LLC (US) 2026-01-29 US disclosed
WO-2024151638-A2 COMPOUNDS FOR FGFRS INHIBITORS COGENT BIOSCIENCES, INC. (US) 2024-07-18 WO disclosed
EP-3615537-B1 6-6 FUSED BICYCLIC HETEROARYL COMPOUNDS AND THEIR USE AS LATS INHIBITORS NOVARTIS AG (CH) 2024-03-06 EP disclosed
US-20230312548-A1 SUBSTITUTE FUSED IMIDAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF VTV THERAPEUTICS LLC 2023-10-05 US disclosed
US-20230190751-A1 6-6 Fused Bicyclic Heteroaryl Compounds and their Use as LATS Inhibitors NOVARTIS INSTITUTE FOR FUNTIONAL GENOMICS, INC., DBA GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION 2023-06-22 US disclosed
US-11649230-B2 Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof VTV THERAPEUTICS LLC (US) 2023-05-16 US disclosed
US-11458138-B2 6-6 fused bicyclic heteroaryl compounds and their use as LATS inhibitors NOVARTIS AG (CH) 2022-10-04 US disclosed
US-20220169641-A1 Substituted Fused Imidazole Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof VTVX HOLDINGS II LLC 2022-06-02 US disclosed
US-20210338644-A1 Substituted Fused Imidazole Derivatives and Methods of Treating Sickle Cell Disease and Related Complications VTV THERAPEUTICS LLC 2021-11-04 US disclosed
US-11130753-B2 Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof VTV THERAPEUTICS LLC (US) 2021-09-28 US disclosed
US-20080103139-A1 3-Carbamoyl-2-Pyridone Derivative SHIONOGI & CO. LTD. (JP) 2008-05-01 US disclosed
US-20080058391-A1 NOVEL COMPOUNDS GLAXO GROUP LIMITED (GB) 2008-03-06 US disclosed
US-20080058391-A1 NOVEL COMPOUNDS GLAXO GROUP LIMITED (GB) 2008-03-06 US disclosed
WO-2008017691-A1 PYRIDINE DERIVATIVES AS SODIUM CHANNEL BLOCKERS GLAXO GROUP LIMITED (GB) 2008-02-14 WO disclosed
US-20070219210-A1 Amidopyrazole Derivative DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-09-20 US disclosed
EP-1806342-A1 3-CARBAMOYL-2-PYRIDONE DERIVATIVE SHIONOGI & CO., LTD. (JP) 2007-07-11 EP disclosed
WO-2006089276-A2 PHARMACOKINETICALLY IMPROVED COMPOUNDS SURFACE LOGIX, INC. (US) 2006-08-24 WO disclosed
WO-2006089275-A2 METHODS OF MAKING PHARMACOKINETICALLY IMPROVED COMPOUNDS COMPRISING FUNCTIONAL RESIDUES OR GROUPS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAID COMPOUNDS SURFACE LOGIX, INC. (US) 2006-08-24 WO disclosed
EP-1587800-A1 THIAZOLE DERIVATIVES AND THEIR USE AS VAP-1 INHIBITORS Astellas Pharma Inc. (JP) 2005-10-26 EP disclosed
WO-2004067521-A1 THIAZOLE DERIVATIVES AND THEIR USE AS VAP-1 INHIBITORS ASTELLAS PHARMA INC. (JP) 2004-08-12 WO disclosed